Estimating the cost of Covid-19 antiviral development
Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
Iovance bulls should focus on execution
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.
Esperion shifts to show not tell
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Astra turns to bispecifics to solve the treme problem
Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
Glaxo and Merck go on the big pharma diet
Glaxosmithkine and Merck & Co succumb to the urge to demerge, joining other big drug makers in pruning their businesses.
Big-caps join the coronavirus scramble
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Philips sells the household goods and could spend on tech instead
Digital health is a core focus for Philips. Might more acquisitions be on the way?
New Pfizer, same problem
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
